- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02913196
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
This is a multi-center, Phase I study of apalutamide in combination with abiraterone acetate, docetaxel and prednisone in patients with metastatic mastrate resistant prostate cancer (mCRPC).
This study is designed to determine the dose that apalutamide can be administered safely in combination with abiraterone acetate, docetaxel and prednisone.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects are enrolled in up to three 3-6-subject cohorts and are administered combination (apalutamide, abiraterone acetate and docetaxel plus prednisone) according to a dose-escalation schedule. The first dose of docetaxel infusion begins on Day 1 Cycle 1. Daily oral apalutamide, abiraterone acetate plus twice-daily oral prednisone begins on Day 1 Cycle 1. Docetaxel 1-hour infusions are administered intravenously every 3 weeks (Q3W), preceded by oral dexamethasone. While a subject is receiving chemotherapy, a treatment cycle is defined as 21 days. Dose limiting toxicity (DLT) determination is based on toxicities observed within the initial 2 cycles defined as 6 weeks. DLT will be assessed before the start of the third docetaxel infusion. Once a combination dose is determined to be safe (i.e. no more than 2 of 6 subjects experience DLT), the next cohort will enroll. Subjects remain at their allocated combination dose until the maximum tolerated dose (MTD) is determined.
The primary objective is to determine a safe dose combination of apalutamide plus abiraterone acetate, docetaxel, prednisone in subjects with mCRPC.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- GU Research Network/Urology Cancer Center
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Histologically or cytologically confirmed adenocarcinoma of prostate
Documented progressive metastatic CRPC based on at least one of the following criteria:
- PSA progression according to Prostate Cancer Working Group 3 (PCWG3) criteria
- Objective radiographic progression in soft tissue, according to modified Response Evaluation Criteria In Solid Tumors (RECIST) or bone scans
- ECOG performance status of 0-2
- Have serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH/GnRH analogue (agonist/antagonist) if they have not undergone orchiectomy
- Age >18 years
Patients must have normal organ and marrow function as defined below:
- Absolute neutrophil count >1,500/cells/mm3
- Hemoglobin ≥ 9 g/dL
- Platelet count >100,000 x 109/microliter
- Serum creatinine <1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault
- Serum albumin ≥3.2 g/dL
- Serum potassium ≥3.5 mmol/L
- Patients must be able to take oral medication without crushing, dissolving or chewing tablets
- Ability to understand and the willingness to sign a written informed consent document
- Medications known to lower the seizure threshold (see list under prohibited medications) must be discontinued or substituted at least 4 weeks prior to study drug initiation
- Patients on stable dose of bisphosphonates or RANK-L inhibitor, Denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication
Exclusion Criteria
Liver Function
- If total bilirubin is >1.5 x ULN (NOTE: in subjects with Gilbert's syndrome, if total bilirubin is >1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is within normal range, subject may be eligible) or
- Alanine (ALT) or aspartate (AST) aminotransferase >1.5xULN (or >5xULN for subject with liver metastasis) concomitant with alkaline phosphatase >2.5xULN (or >5xULN for subjects with bone or liver metastases) or
- Alanine (ALT or aspartate (AST) aminotransferase >2.5xULN (or >5xULN for subjects with liver metastasis
- Use of investigational drugs (including vaccines) or implantation of invasive medical device ≤4 weeks or <5 half-lives of Cycle 1, Day 1 or current enrollment in investigational drug or device study
- Prior exposure to apalutamide. Prior exposure to abiraterone acetate and/or other CYP17 inhibitors, enzalutamide is allowed (but not preferred) only during the dose escalation period
- Prior chemotherapy for advanced prostate cancer. Prior chemotherapy for any other disease within 3 years
- Prior systemic beta-emitting bone-seeking radioisotopes (i.e. strontium-90)
- Pre-existing neuropathy ≥Grade 2
- Systemic azole treatment (e.g. Fluconazole, itracanozole) ≤2 weeks of Cycle 1 Day 1
- Use of potent inducers or inhibitors of CYP3A4 activity ≤2 weeks prior to Day 1 Cycle 1
- History of adrenal insufficiency or hyperaldosteronism
- Active or symptomatic viral hepatitis
- Chronic liver disease
- Brain metastases or leptomeningeal disease
- Known allergies, hypersensitivity or intolerance to abiraterone acetate, apalutamide, docetaxel, dexamethasone, prednisone, or their excipients
- Use of herbal, alternative and food supplements (i.e. PC-Spes, Saw Palmetto, St John Wort, etc) must be discontinued before treatment start. Daily Multi-vitamin, calcium and Vitamin D is allowed
- Surgery or local prostatic intervention within 30 days of first dose. [Note: Any clinically relevant sequelae from surgery must have resolved prior to Day 1 Cycle 1]
- Radiation therapy for treatment of prostate cancer ≤4 weeks of Day 1 Cycle 1
Current evidence of any of the following:
- Uncontrolled hypertension (defined as blood pressure of >150 mmHg systolic and/or >100 mmHg diastolic on medication)
- Gastrointestinal disorder affecting absorption
- Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated
- Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/prednisolone once daily
- Any condition that in the opinion of the investigator, would preclude participation in this study
- Patients with baseline severe hepatic impairment (Child Pugh Class C)
- Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to treatment start or New York Heart Association (NYHA) Class II to IV heart disease
- Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
- Having partners of childbearing potential and not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 week after last study drug administration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All patients
Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2
|
Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor. Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD
Other Names:
Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone. Dose: 1000 mg QD
Other Names:
Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer. Dose: 75 mg/m2 Q3W
Other Names:
Dose: 5 mg BID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with dose limiting toxicities (DLT)
Time Frame: From the time of study drug administration till PSA progression or study completion (~36 months)
|
Dose limiting toxicities will be measured by using the Common Terminology Criteria for Adverse Events or CTCAE version 4.0 which uses a grading scale from 1-5.
|
From the time of study drug administration till PSA progression or study completion (~36 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the number of subjects with prostate-specific antigen (PSA) response
Time Frame: Starting after 12 weeks, at the beginning of Week 4 of combination therapy with docetaxel, apalutamide, abiraterone acetate plus prednisone until PSA progression or study completion (~36 months)
|
Starting after 12 weeks, at the beginning of Week 4 of combination therapy with docetaxel, apalutamide, abiraterone acetate plus prednisone until PSA progression or study completion (~36 months)
|
|
Change in PSA response
Time Frame: At the start of treatment until PSA progression or study completion (~36 months)
|
PSA response will be captured through blood sample collection and radiographic scans
|
At the start of treatment until PSA progression or study completion (~36 months)
|
Change in the time to PSA progression
Time Frame: At the start of treatment until PSA progression or study completion (~36 months)
|
PSA progression will be determined by protocol-specific/modified Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria
|
At the start of treatment until PSA progression or study completion (~36 months)
|
Change is radiographic progression-free survival
Time Frame: Images will be collected at baseline, 12 weeks and at end of study, an average of 100 months
|
Radiographic progression will be determined via scans metric of CT, MRI and Bone scans
|
Images will be collected at baseline, 12 weeks and at end of study, an average of 100 months
|
Change in CellSearch circulating tumor cells (CTC) enumration
Time Frame: Collected at baseline, 12 weeks and at end of study, an average of 100 months
|
CTCs will be collected via blood sample collection
|
Collected at baseline, 12 weeks and at end of study, an average of 100 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ana Molina, MD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Docetaxel
- Prednisone
- Abiraterone Acetate
Other Study ID Numbers
- 1509016578
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer Metastatic
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.Active, not recruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
WntResearch ABCompletedMetastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Colon CancerDenmark, United Kingdom
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
Clinical Trials on Apalutamide
-
Aragon Pharmaceuticals, Inc.Active, not recruitingProstatic NeoplasmsUnited States, Australia, France, Poland, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Romania, Japan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Hungary, Austria, Sweden, Slovaki... and more
-
Kindai UniversityJanssen Pharmaceutical K.K.RecruitingMetastatic Castration-sensitive Prostate CancerJapan
-
Aragon Pharmaceuticals, Inc.CompletedCastration-Resistant Prostate CancerUnited States, Canada, Netherlands, United Kingdom, Moldova, Republic of
-
Janssen Research & Development, LLCRecruitingHepatic ImpairmentUnited States
-
Edwin Posadas, MDEnviro Therapeutics, Inc.RecruitingCastration-resistant Prostate CancerUnited States
-
Janssen Research & Development, LLCWithdrawn
-
Zhujiang HospitalRecruitingHigh-Risk and Oligometastatic Prostate CancerChina
-
BayerCompletedNon-metastatic Castration-resistant Prostate CancerUnited States
-
BayerActive, not recruitingNon-metastatic Castration-resistant Prostate CancerUnited States
-
Chinese University of Hong KongJanssen, LPTerminated